The uptake and metabolism of (32-P)pyrophosphate by mouse calvaria in vitro

Synthesis and evaluation of a novel 99m Tc nitrido radiopharmaceutical with alendronate dithiocarbamate as a potential bone-imaging agent

Currently, a popular strategy for designing novel radioprobes as bone-imaging agents is based on the concept of bifunctional radiopharmaceuticals. Considering the dithiocarbamate ligand can act as a suitable bifunctional linking agent to attach technetium-99m (^99m Tc) to corresponding target molecules, in this study, alendronate dithiocarbamate (ALNDTC) was synthesized and radiolabeled with [^99m Tc≡N]²⁺ core by ligand exchange reaction to produce ^99m TcN-ALNDTC complex, for the potential use as a novel probe for bone imaging. The radiochemical purity of the complex was over 90%. The complex was stable in vitro and could bind to hydroxyapatite. The partition coefficient result indicated it was hydrophilic, and an evaluation of biodistribution in mice indicated that the complex exhibited a higher bone uptake than did ^99m Tc-labeled methylenediphosphonate (^99m Tc-MDP). Further, single photon emission computed tomography imaging study indicated clear accumulation in bone, suggesting that ^99m TcN-ALNDTC would be a promising candidate for bone imaging.

Bisphosphonates: the first 40 years

The first full publications on the biological effects of the diphosphonates, later renamed bisphosphonates, appeared in 1969, so it is timely after 40years to review the history of their development and their impact on clinical medicine. This special issue of BONE contains a series of review articles covering the basic science and clinical aspects of these drugs, written by some of many scientists who have participated in the advances made in this field. The discovery and development of the bisphosphonates (BPs) as a major class of drugs for the treatment of bone diseases has been a fascinating story, and is a paradigm of a successful journey from 'bench to bedside'. Bisphosphonates are chemically stable analogues of inorganic pyrophosphate (PPi), and it was studies on the role of PPi as the body's natural 'water softener' in the control of soft tissue and skeletal mineralisation that led to the need to find inhibitors of calcification that would resist hydrolysis by alkaline phosphatase. The observation that PPi and BPs could not only retard the growth but also the dissolution of hydroxyapatite crystals prompted studies on their ability to inhibit bone resorption. Although PPi was unable to do this, BPs turned out to be remarkably effective inhibitors of bone resorption, both in vitro and in vivo experimental systems, and eventually in humans. As ever more potent BPs were synthesised and studied, it became apparent that physico-chemical effects were insufficient to explain their biological effects, and that cellular actions must be involved. Despite many attempts, it was not until the 1990s that their biochemical actions were elucidated. It is now clear that bisphosphonates inhibit bone resorption by being selectively taken up and adsorbed to mineral surfaces in bone, where they interfere with the action of the bone-resorbing osteoclasts. Bisphosphonates are internalised by osteoclasts and interfere with specific biochemical processes. Bisphosphonates can be classified into at least two groups with different molecular modes of action. The simpler non-nitrogen containing bisphosphonates (such as etidronate and clodronate) can be metabolically incorporated into non-hydrolysable analogues of ATP, which interfere with ATP-dependent intracellular pathways. The more potent, nitrogen-containing bisphosphonates (including pamidronate, alendronate, risedronate, ibandronate and zoledronate) are not metabolised in this way but inhibit key enzymes of the mevalonate/cholesterol biosynthetic pathway. The major enzyme target for bisphosphonates is farnesyl pyrophosphate synthase (FPPS), and the crystal structure elucidated for this enzyme reveals how BPs bind to and inhibit at the active site via their critical N atoms. Inhibition of FPPS prevents the biosynthesis of isoprenoid compounds (notably farnesol and geranylgeraniol) that are required for the post-translational prenylation of small GTP-binding proteins (which are also GTPases) such as rab, rho and rac, which are essential for intracellular signalling events within osteoclasts. The accumulation of the upstream metabolite, isopentenyl pyrophosphate (IPP), as a result of inhibition of FPPS may be responsible for immunomodulatory effects on gamma delta (γδ) T cells, and can also lead to production of another ATP metabolite called ApppI, which has intracellular actions. Effects on other cellular targets, such as osteocytes, may also be important. Over the years many hundreds of BPs have been made, and more than a dozen have been studied in man. As reviewed elsewhere in this issue, bisphosphonates are established as the treatments of choice for various diseases of excessive bone resorption, including Paget's disease of bone, the skeletal complications of malignancy, and osteoporosis. Several of the leading BPs have achieved 'block-buster' status with annual sales in excess of a billion dollars. As a class, BPs share properties in common. However, as with other classes of drugs, there are obvious chemical, biochemical, and pharmacological differences among the various BPs. Each BP has a unique profile in terms of mineral binding and cellular effects that may help to explain potential clinical differences among the BPs. Even though many of the well-established BPs have come or are coming to the end of their patent life, their use as cheaper generic drugs is likely to continue for many years to come. Furthermore in many areas, e.g. in cancer therapy, the way they are used is not yet optimised. New 'designer' BPs continue to be made, and there are several interesting potential applications in other areas of medicine, with unmet medical needs still to be fulfilled. The adventure that began in Davos more than 40 years ago is not yet over.

Inorganic pyrophosphatase activity of purified bovine pulp alkaline phosphatase at physiological pH

At physiological pH, the hydrolytic activity of purified bovine pulp alkaline phosphatase toward phosphorus compounds was observed to be in the order of inorganic pyrophosphate greater than beta-glycerophosphate greater than phosphorylcholine greater than p-nitrophenylphosphate greater than glucose-6-phosphate. Optimum pH of the enzyme toward inorganic pyrophosphate was shown to be 8.5, with around 60% of the activity at pH 7.5. The activity was increased by the addition of Mg2+, but a different pattern of activation was observed between pH 7.5 and 8.5.

Changes in pyrophosphatase activity during the de novo mineralization associated with cartilage and bone formation

Pyrophosphatase was extracted from implants undergoing de novo mineralization in an in vivo model of matrix-induced endochondral bone formation. Before the onset of the mineralization of the plaques and after the mineralization process had been completed only one form of pyrophosphatase activity was observed. During the active deposition of calcium phosphate, however, a new, higher molecular weight form of pyrophosphatase activity was produced suggesting that this enzyme activity is associated with biological mineralization. This observation gives support to the earlier suggestion that inhibitors of calcium phosphate precipitation, such as pyrophosphate, must be removed from the site of mineralization before calcification can occur. This high-molecular-weight activity also appears to be associated with alkaline and/or acid phosphatase activity as determined by molecular exclusion chromatography.

Can biological calcification occur in the presence of pyrophosphate?

It was shown that it is apparently impossible for any calcification to occur in a system which contains a constant, physiological concentration of inorganic pyrophosphate. These results give further support to the earlier suggestion that inhibitors of calcium phosphate crystal growth must be removed from or denied access to the site of calcification to allow for the normal formation of the mineral phase. This study also suggests that the means of assessing the relative importance of a calcification inhibitor should be altered, since it is the equilibrium concentration of an inhibitor, and not its initial concentration in an assay system, which has physiological relevance.

High affinity calcium binding peptides from the gills, gut and kidneys of the freshwater eel (Anguilla anguilla)

We report the isolation of high affinity calcium-binding peptides from homogenates of gills, gut and kidneys of the freshwater eel Anguilla anguilla. These peptides show identical gel-filtration profiles on Biogel P-6, from which a molecular weight of 3500 was estimated. The average binding constant (Kf) for calcium is 7 . 10(7)M-1, and MgCl2 up to 5 mM does not displace calcium.

The influx of pyrophosphate ions into calvaria in vitro

The flux of 32P-labeled inorganic pyrophosphate (PPi) into bone was studied in vitro using Ussing chamber techniques and calvaria from newborn rat pups. Because insignificant hydrolysis and backflux of PPi took place under experimental conditions, it was possible to study the penetration of bone membranes by PP1 unambiguously. At physiological concentrations, the influx was found to be linearly concentration dependent and to follow first order kinetics, apparently a simple diffusion process. In magnitude, the intrinsic constant for influx was found to be approximately one-half that of inorganic phosphate ions under comparable conditions.

[Origin and fixation of pyrophosphates in the parietal bones of young rats]

Calvaria from 6 to 13-day-old rats mineralize and bind pyrophosphates which are transferred from nucleotides, as shown by : 1 -- the increase of pyrophosphates in young rat calvaria incubated with nucleoside triphosphate, especially ATP ; 2 -- the more important increase of pyrophosphate content when ATP is renewed in the incubation medium ; and 3 -- binding of [32P] pyrophosphate [beta 32P] ATP. The effect of preheating of calvaria on 32P binding from [beta32P]ATP led us to assume that two systems might be involved in pyrophosphate fixation : a heat-labile, non-specific, phosphatase system, and a heat-stable pyrophosphotransferase system. cAMP increases the pyrophosphate content of calvaria incubated with ATP : that effect may result from either an inhibition of the phosphatase system, or an activation of the pyrophosphotransferase system.